Home / Healthcare/ Long-acting injection a shot in the arm for GSK’s HIV business

Long-acting injection a shot in the arm for GSK’s HIV business


Comments / {{hitsCtrl.values.hits}} Views / Thursday, 16 August 2018 00:00


Reuters: A long-acting injection developed by GlaxoSmithKline and given once a month has proved as effective as standard daily pills for controlling the AIDS virus, lifting prospects for the British drugmaker’s key HIV business.

GSK’s majority-owned ViiV Healthcare unit said yesterday that the experimental two-drug injection of cabotegravir and rilpivirine maintained similar rates of viral suppression compared with a standard three-drug oral regimen after 48 weeks of a clinical trial.

The result from the big Phase III study is a boost for GSK’s goal of developing dual therapies that are easier to tolerate than conventional triple ones, and shares in GSK rose 1.5%. It follows recent positive data from combining two oral drugs.

GSK hopes its new approach will allow it to compete more effectively against Gilead Sciences, the US drugmaker that dominates the $ 26 billion-a-year HIV market.

Shares in Gilead, which also announced late on Tuesday that its Chief Medical Officer Andrew Cheng was leaving the company, fell 3%.

Gilead currently has a market share of around 52% against GSK’s 22%, but Deborah Waterhouse, who heads the British drugmaker’s HIV unit, says she hopes to overtake her US rival by the mid-2020s.

That is a bold ambition, since many analysts have been expecting GSK to lose market share to Gilead’s new triple drug Biktarvy, rather than see it gain ground.



Slow burn

Liberum analyst Roger Franklin, who rates GSK a ‘buy’, believes the company’s dual-drug strategy has been under-appreciated by the market.

“Whilst duals will likely be a slow burn as resistance data is collected and the regimen gains credence among physicians, the prospects are much improved now versus a year ago,” he said.

GSK is betting that a shift to using two drugs rather than three will boost its sales by offering patients a therapy with greater convenience and fewer toxic side effects. In certain cases, depending on the drugs used, two-drug regimens will also be significantly cheaper.

Still, some doctors worry that using just two drugs to keep the AIDS virus at bay might risk drug resistance because HIV will only have to evade two drugs rather than three. That is certainly the view at Gilead, which is sticking with three.

In the case of the cabotegravir and rilpivirine monthly injection, GSK said drug resistance results in the latest study were consistent with data from earlier smaller trials. It did not go into further details but said full results would be presented at an upcoming scientific meeting.

ViiV Chief Scientific and Medical Officer John Pottage argued the novel injection offered an alternative long-term treatment for patients.

“If approved, this regimen would give people living with HIV one month between each dose of antiretroviral therapy, changing HIV treatment from 365 dosing days per year, to just 12,” he said.

Results from a second trial of cabotegravir and rilpivirine are expected later this year. Rilpivirine was developed by Johnson and Johnson and GSK is working with the US drugmaker on the new injection regimen.


Share This Article


DISCLAIMER:

1. All comments will be moderated by the Daily FT Web Editor.

2. Comments that are abusive, obscene, incendiary, defamatory or irrelevant will not be published.

3. We may remove hyperlinks within comments.

4. Kindly use a genuine email ID and provide your name.

5. Spamming the comments section under different user names may result in being blacklisted.

COMMENTS

Today's Columnists

Constitutional paradox: There is no such thing called Election Commission

Wednesday, 14 November 2018

Our Constitution, which was certified by Parliament on 31 August 1978, has 19 amendments; the First Amendment to the Constitution was certified by the Speaker in the same year on 20 November. By the end of 1988, there had been 14 amendments made to t


‘So Sri Lanka’ – upgrade staff, processes, infrastructure at BIA arrivals to be world’s best!

Wednesday, 14 November 2018

24 October, time 12:47 p.m., place – my residence in Colombo My phone buzzes with a WhatsApp message from my old colleague Prasad Fernanado now with Saudi British Bank in Saudi. I am thrilled to see the message ‘Sri Lanka top country for travel i


Qatar crisis: From the Sri Lankans’ point of view

Wednesday, 14 November 2018

The aim of this article is to examine the Saudi blockade over Qatar and its impact in the past 17 months on the country. A special focus will be given to the Sri Lankan workers who have been living in Qatar for the past two decades. The reason why th


The reality of Sri Lanka – household end!

Wednesday, 14 November 2018

Whilst Sri Lanka is debating what is right and wrong on the governance of the country, the Sri Lankan household is falling part due to escalating costs, as per the latest data released by respected research agency Nielsen. For the seventh quarter in


Columnists More